Drug Profile
MAGE A3 TCR
Alternative Names: Anti-MAGE A3 HLA-A-01-restricted TCR; Anti-MAGE-A3-DP4-TCR; Anti-MAGE-A3-TCRLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Kite Pharma; National Cancer Institute (USA)
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 24 Mar 2021 National Cancer Institute completes a phase I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (NCT02111850)
- 04 Oct 2019 MAGE-A3 TCR is still in phase I/II trials for Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (IV) (NCT02111850)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences